Skip to content
CSE: XRX.CN 0.24 +0.04 +20.00%  
XORTX
  • About
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Autosomal Dominant Polycystic Kidney Disease
    • Diabetic Nephropathy
    • Metabolic Syndrome / Diabetes
    • Hypertension
  • Strategic Partnerships
  • Investors
    • Press Releases
    • Presentations
    • Financials
    • SEDAR
    • Transfer Agent
    • Upcoming Events
  • Contact
Site Search

Business Development References

  1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2–220.
  2. Lee JM, Okumura MJ, et al. Prevelance and determinants of insulin resistance among U.S. adolescents.  Diabetes Care. 2006; 29:2427-2432.
  3. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.
  4. Mazzali M, Hughes J, Kim YG, et al.: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001, 38:1101–1106.
  5. Sanchez-Lozada LG, Tapia E, Soto V, et al.: Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant 2007, 23:1179–1185.
  6. Daniel I. Feig; Beth Soletsky; Richard J. Johnson, Effect of allopurinol on blood pressure of adolescents with newly diagnosed  essential hypertension: A randomized trial.  JAMA. 2008;300(8):924-932.
  7. Soletsky B, Feig D, Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension, 60:1148-1156, 2012.
  8. Matsura F, Yamashita S, Nakamura T, et al., Effect of  visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is lined more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism 1998, 47:929-933.
  9. Borges, RL, Riberio, AB, Zanella MT, Batista MC, Uric acid as a factor in the metabolic syndrome. Curr Hypertens Rep (2010) 12L113-119.
  10. Maahs D.M. et al., Uric acid lowering to prevent kidney function loss in diabetes: The Prevention Early Renal Function Loss ( PERL) Allopurinol Study.  Curr Diab Res., May 07, 2013.
  11. Jalal DI, et al Serum Uric acid level predict the development of albuminuria over 6 years in patients with type I diabetes: findings from the Coronary Artery Clacification in Type I Diabetes Study, Nephropl Dial Transplant 2012; 25:1865-1869.
  12. Hovingd P, et al Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study, Diabetes 2009;58:1668-71.
  13. Ficociello LH, et al High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care 2010;33:1337-43.
  14. Goicoechia M et al, Effect of allopurinol in chronic kidney disease progression and cardiovascular risk, Clin J Am Soc Nephrol 5: 1388-1393, 2010.
  15. Siu Y-P, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level, Am J Kidney Dis 47: 51-59, 2005.
     

 

Leave a Reply Cancel reply

Your email address will not be published.

Press Releases

  • XORTX to Present at NobleConXV Noble Capital Markets’ 15th Annual Investor Conference January 28, 2019
  • XORTX Receives FDA Response on Orphan Drug Designation Application November 26, 2018
  • XORTX Announces Appointment of CFO November 6, 2018
  • XORTX Announces Revision to Polycystic Kidney Disease Clinical Development Plan October 23, 2018
  • XORTX Announces New Clinical Advisory Board Members October 15, 2018
XORTX Therapeutics Inc.
4000, 421 7th Avenue SW
Calgary, Alberta T2P 4K9
Ph: +1 (403) 455-7727
info@xortx.com
Theme by Colorlib Powered by WordPress